Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

768.35INR
3:56pm IST
Price Change (% chg)

Rs-35.25 (-4.39%)
Prev Close
Rs714.60
Open
Rs808.80
Day's High
Rs808.80
Day's Low
Rs762.00
Volume
3,615,344
Avg. Vol
891,151
52-wk High
Rs811.00
52-wk Low
Rs496.40

LUPN.NS

Chart for LUPN.NS

About

Lupin Limited is a transnational pharmaceutical Company. The Company is engaged in producing a range of generic and branded formulations and bulk drugs. It manufactures Active Pharmaceutical Ingredients (APIs) and several drug formulations. Its product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma,... (more)

Overall

Beta: 0.46
Market Cap (Mil.): Rs359,721.19
Shares Outstanding (Mil.): 447.64
Dividend: 4.00
Yield (%): 0.40

Financials

  LUPN.NS Industry Sector
P/E (TTM): 33.95 35.66 35.83
EPS (TTM): 23.67 -- --
ROI: -- 19.36 18.72
ROE: -- 20.07 19.54
Search Stocks

Latest News about LUPN.NS

Lupin falls; Mylan launches cholesterol drug

Reuters Market Eye - Shares in Lupin Ltd slump 4 percent after earlier falling as much as 4.7 percent following the launch of rival Mylan Inc's generic version of the cholesterol-lowering Tricor tablets.

10:48am IST

MARKET EYE-India's Lupin falls; Mylan launches cholesterol drug

* Shares in Lupin Ltd slump 4 percent after earlier falling as much as 4.7 percent following the launch of rival Mylan Inc's generic version of the cholesterol-lowering Tricor tablets. * Mylan Inc said in a statement on Friday its unit Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg. * Mylan compete against Lupin, which also sells generic versions of Tricor. * "Mylan's launch of Tricor will result in higher competition and decline in Lupin's ma

10:25am IST

MARKET EYE-Indian shares gain; HDFC, Lupin gain after earnings

* India's main share index gains 0.33 percent, while the broader NSE index is 0.21 percent higher, after hitting new three-month highs earlier in the day, on buoyant foreign inflows and higher Asian shares. * Foreign portfolio investors have bought $12.34 billion of Indian stocks in 2013. * Asian shares rose on Wednesday on another record high for U.S. stocks and unexpectedly strong German industrial orders. * Housing Development Finance Corp (HDFC), India's biggest mortgage lender, up 2.9

08 May 2013

TABLE-India's Lupin Q4 net more than doubles

MUMBAI, May 8 - Three months ended March 31 (Versus the same period a year earlier, in billion rupees unless stated) Net Profit 4.08 vs 1.56 Net Sales 25.37 vs 18.83 Results are consolidated. NOTE: Lupin Ltd is a drugmaker. (Reporting by Kaustubh Kulkarni; Editing Anupama Dwivedi)

08 May 2013

Lupin operating profit may lag estimates - StarMine

Reuters Market Eye - Lupin Ltd may miss January-March operating profit consensus forecasts when it reports results later in the day, according to Thomson Reuters StarMine data.

08 May 2013

MARKET EYE-India's Lupin operating profit may lag estimates-StarMine

* India's Lupin Ltd may miss January-March operating profit consensus forecasts when it reports results later in the day, according to Thomson Reuters StarMine data. * StarMine's SmartEstimates, which places greater emphasis on forecasts by top-rated analysts, expects Lupin to report an operating profit of 5.37 billion rupees ($99 million) for the quarter compared with a wider consensus mean estimate of 5.51 billion rupees. * Shares in Lupin are up 2.1 percent at 0525 GMT. ($1 = 54.0950 I

08 May 2013

India's Lupin launches generic Diovan HCT tablets in the U.S.

* Launches generic version of Diovan HCT tablets in the United States.

22 Mar 2013

Lupin plans to launch 3-4 generic drugs in U.S. by end-March

MUMBAI - Lupin Ltd, India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.

31 Jan 2013

India's Lupin plans to launch 3-4 generic drugs in U.S. by end-March

MUMBAI, Jan 31 - Lupin Ltd, India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.

31 Jan 2013

TABLE-Lupin Oct-Dec net up 42.6 pct, beats forecast

MUMBAI, Jan 31 - Three months ended Dec 31 (Versus the same period a year earlier, in billion rupees unless stated) Net Profit 3.35 vs 2.35 Net Sales 24.66 vs 17.92 Results are consolidated. Estimate for net profit: 2.94 bln rupees NOTE: Lupin Ltd is a Mumbai-based drugmaker. (Reporting by Kaustubh Kulkarni; Editing by Jijo Jacob)

31 Jan 2013
» More LUPN.NS News

Earnings vs. Estimates

Search Stocks